- Title
- Resveratrol does not benefit patients with non-alcoholic fatty liver disease
- Creator
- Chachay, Veronique S.; Macdonald, Graeme A.; Coombes, Jeff S.; Thomas, Gethin P.; Cowin, Gary J.; Kirkpatrick, Carl M. J.; Prins, Johannes B.; Hickman, Ingrid J.; Martin, Jennifer H.; Whitehead, Jonathan P.; O'Moore-Sullivan, Trisha M.; Lee, Paul; Franklin, Michael; Klein, Kerenaftali; Taylor, Paul J.; Ferguson, Maree
- Relation
- Clinical Gastroenterology and Hepatology Vol. 12, Issue 12, p. 2092-2103
- Publisher Link
- http://dx.doi.org/10.1016/j.cgh.2014.02.024
- Publisher
- W.B. Saunders
- Resource Type
- journal article
- Date
- 2014
- Description
- Background & Aims: Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD. Methods: Overweight or obese men diagnosed with NAFLD were recruited from hepatology outpatient clinics in Brisbane, Australia from 2011 through 2012. They were randomly assigned to groups given 3000 mg resveratrol (n= 10) or placebo (n= 10) daily for 8 weeks. Outcomes included insulin resistance (assessed by the euglycemic-hyperinsulinemic clamp), hepatic steatosis, and abdominal fat distribution (assessed by magnetic resonance spectroscopy and imaging). Plasma markers of inflammation, as well as metabolic, hepatic, and antioxidant function, were measured; transcription of target genes was measured in peripheral blood mononuclear cells. Resveratrol pharmacokinetics and safety were assessed. Results: Eight-week administration of resveratrol did not reduce insulin resistance, steatosis, or abdominal fat distribution when compared with baseline. No change was observed in plasma lipids or antioxidant activity. Levels of alanine and aspartate aminotransferases increased significantly among patients in the resveratrol group until week 6 when compared with the placebo group. Resveratrol did not significantly alter transcription of NQO1, PTP1B, IL6, or HO1 in peripheral blood mononuclear cells. Resveratrol was well-tolerated. Conclusions: Eight weeks administration of resveratrol did not significantly improve any features of NAFLD, compared with placebo, but it increased hepatic stress, based on observed increases in levels of liver enzymes. Further studies are needed to determine whether agents that are purported to mimic calorie restriction, such as resveratrol, are safe and effective for complications of obesity. Clinical trials registration no: ACTRN12612001135808.
- Subject
- NAFLD; obesity-related fatty liver; chronic disease; ALT; AST
- Identifier
- http://hdl.handle.net/1959.13/1297571
- Identifier
- uon:19484
- Identifier
- ISSN:1542-3565
- Language
- eng
- Reviewed
- Hits: 14092
- Visitors: 14176
- Downloads: 0